A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 8, 2021

Primary Completion Date

December 7, 2023

Study Completion Date

January 30, 2024

Conditions
Renal Cell CarcinomaGastric CancerMetastatic Breast CancerSmall-cell Lung CancerOther Solid Tumors
Interventions
DRUG

HC-5404-FU

HC 5404-FU (hemi fumarate salt of HC 5404) is a novel, highly selective, and potent PERK inhibitor. Preclinical pharmacological studies demonstrated high specificity of HC 5404-FU to PERK and decreased viability of tumor cells. HC 5404-FU will be orally administered BID every day with food or within 30 minutes of completing a meal, starting at 25 mg, with doses escalating to 50, 100, 200, 400, 600, and 900 mg BID as safety allows for each 3-week treatment cycle.

Trial Locations (4)

48201

Karmanos Cancer Institute, Detroit

55101

HealthPartners Cancer Care Center, Saint Paul

75246

Baylor University Medical Center, Dallas

77030

The University of Texas M.D. Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

HiberCell, Inc.

INDUSTRY